Exposures to hazardous airborne particles can pose a significant health risk to those routinely exposed in ambient air and industrial work environments. Measuring chemical composition and concentration of aerosol particles is important to preventing worker exposures and protecting health.
CDC NIOSH early technology to detect surface contamination by hazardous antineoplastic drugs. Antineoplastic drugs, also known as anti-cancer drugs or chemotherapy, are used in the treatment of many types of cancer. While these drugs are lifesaving to patients, they must be handled with care by healthcare workers. Exposure from contaminated surfaces and drug vials can cause skin problems, birth defects, reproductive issues, and increased risk of various cancers.
CDC NIOSH early technology to detect surface contamination by hazardous antineoplastic drugs. Antineoplastic drugs, also known as anti-cancer drugs or chemotherapy, are used in the treatment of many types of cancer. While these drugs are lifesaving to patients, they must be handled with care by healthcare workers. Exposure from contaminated surfaces and drug vials can cause skin problems, birth defects, reproductive issues, and increased risk of various cancers.
Researchers at the Centers for Disease Control and Prevention (CDC) developed a low-cost technology to rapidly detect HIV-1 drug resistance (HIVDR) in plasma and dried blood spot (DBS) samples with 95.8% genotyping sensitivity. CDC’s partners at Life Technologies Corporation (“LifeTech”) have licensed, further developed, and incorporated the technology into a commercialized product. Life Tech’s HIV-1 Genotyping Kit provides a cost-effective assay, scalable workflow, easy-to read sequencing results, and robust test performance.
The Centers for Disease Control and Prevention (CDC) and the National Institute for Allergy and Infectious Diseases (NIAID) have been rewarded for their partnership from the 2021 Federal Laboratory Consortium (FLC) awards. The CDC and NIAID had already developed a new approach to sharing samples during a Public Health Emergency of International Concern (PHEIC) during the Zika pandemic, which enabled them to respond quickly and efficiently to access and share samples of SARS-CoV-2 early in the outbreak.
The Technology Transfer and Intellectual Property Office (TTIPO)
Dr. McCue joined OTT in June 2009. Prior to joining OTT, Dr. McCue was a technology transfer fellow at the National Cancer Institute (NCI)’s Technology Transfer Center. Dr. McCue completed research fellowships at the NCI-Frederick, at the National Center for Complementary and Alternative Medicine (NCCAM), and at the Genome Research Facility of the National Aeronautics and Space Administration (NASA). Registered to practice before the U.S. Patent and Trademark Office, Dr.